Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma?

Chest

Volumn 128, Issue 4, 2005, Pages 2954-2962

  Currie, Graeme P ^a   Lee, Daniel K C ^b   Srivastava, Prasima ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b IPSWICH HOSPITAL   (United Kingdom)

Author keywords

Asthma; Formoterol; Inflammation; Leukotriene receptor antagonist; Long acting 2 agonist; Montelukast; Salmeterol; Zafirlukast

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CETIRIZINE; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MONTELUKAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; ZAFIRLUKAST;

ABDOMINAL PAIN; ADD ON THERAPY; ALGORITHM; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ASTHMA; BRONCHUS HYPERREACTIVITY; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEADACHE; HEART PALPITATION; HUMAN; HYPOKALEMIA; INFLAMMATION; LOEFFLER PNEUMONIA; LUNG FUNCTION; META ANALYSIS; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREMOR;

EID: 27144496334     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2954     Document Type: Review

References (60)

1. Currie GP, Jackson CM, Lipworth BJ. Does bronchial hyperresponsiveness in asthma matter? J Asthma 2004; 41:247-258
2. British guideline on the management of asthma. Thorax 2003; 58(suppl):i1-i94
3. GINA workshop report. Global strategy for asthma management and prevention, updated 2004: scientific information and recommendations for asthma programs. Bethesda, MD: National Institutes of Health; publication No. 02-3659
4. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001; 323:253-256
5. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955
6. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327:891-897
7. Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004; 92:641-648
8. 2-agonists: comparative pharmacology and clinical outcomes. Am J Respir Crit Care Med 2002; 1:55-74
9. Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357:257-261
10. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-136
11. 2-agonists as add-on therapy to inhaled corticosteroids. QJM 2003; 96:435-440
12. Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150:1006-1011
13. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001; 163:881-886
14. McIvor RA, Pizziehini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930
15. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161:996-1001
16. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330:117-120
17. 2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360:1293-1299
18. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274:1005-1010
19. 2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164:117-121
20. Currie GP, Bates CE, Lee DK, et al. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003; 59:11-15
21. Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167:1232-1238
22. Aziz I, Tan KS, Hall IP, et al. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur Respir J 1998; 12:580-584
23. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic closing with salmeterol. Respir Med 1994; 88:363-368
24. Lipworth BJ, Azix, I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol 1999; 103:88-92
25. Currie GP, Devereux GS, Lee DK, et al. Recent developments in asthma management. BMJ 2005; 330:585-589
26. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344:219-224
27. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488
28. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373
29. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170:836-844
30. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-1411
31. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309-2321
32. Dworski R, Fitzgerald GA, Gates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149:953-959
33. Henderson WR Jr., Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165:108-116
34. Currie GP, Lipworth BJ. Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest 2002; 122:146-150
35. Currie GP, Srivastava P, Dempsey OJ, et al. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. QJM 2005; 98:171-182
36. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-reeeptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152
37. Jayaram L, Pizziehini E, Lemiere C, et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax 2005; 60:100-105
38. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003; 326:621-623
39. Dempsey OJ. Leukotriene receptor antagonist therapy. Postgrad Med J 2000; 76:767-773
40. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160:1862-1868
41. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58:204-210
42. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9-14
43. Henriksen JM, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. Am Rev Respir Dis 1984; 130:1014-1018
44. Reed CE, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma symptoms. J Allergy Clin Immunol 1988; 81:1042-1047
45. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116:338-344
46. Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000; 162:1297-1301
47. Wilson AM, Dempsey OJ, Sims EJ, et al. A comparison of topical hudesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31:616-624
48. Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20:1549-1558
49. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284-200
50. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088-1095
51. Ringdal N, Eliraz A, Pruzinee R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97:234-241
52. Wilson AM, Dempsey OJ, Sims EJ, et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119:1021-1026
53. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120:423-430
54. Storms W, Chervinsky P, Ghannam AF, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004; 98:1051-1062
55. Nelson HS, Nathan RA, Kalberg C, et al. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. Med Gen Med 2001; 3:3
56. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47:81-87
57. Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004; 126:1480-1489
58. Camargo CA Jr., Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528-533
59. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007-2011
60. Barnes N, Thomas M, Price D, et al. The national montelukast survey. J Allergy Clin Immunol 2005; 115:47-54